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Antiherpesvirus Activities of Two Novel 4=-Thiothymidine Derivatives,
KAY-2-41 and KAH-39-149, Are Dependent on Viral and Cellular
Thymidine Kinases
Natacha Coen,a Sophie Duraffour,a Kazuhiro Haraguchi,b Jan Balzarini,a Joost J. van den Oord,c Robert Snoeck,a Graciela Andreia*
Rega Institute for Medical Research, KU Leuven, Leuven, Belgiuma; Nihon Pharmaceutical University, Inamachi, Kita-adachi-gun, Saitama, Japanb; Laboratory of
Translational Cell and Tissue Research, University Hospitals Leuven, Leuven, Belgiumc
The emergence of drug-resistant herpesviruses represents a significant problem in clinical practice, primarily in immunocom-
promised patients. Furthermore, effective antiviral therapies against gammaherpesvirus-associated diseases are lacking. Here,
we present two thiothymidine derivatives, KAY-2-41 and KAH-39-149, with different spectra of antiviral activity from those of
the reference antiherpetic drugs, showing inhibitory activities against herpes simplex virus, varicella-zoster virus (VZV), and
particularly against Epstein-Barr virus, with high selectivity in vitro. While KAY-2-41- and KAH-39-149-resistant herpesviruses
were found to harbor mutations in the viral thymidine kinase (TK), these mutations conferred only low levels of resistance to
these drugs but high levels to other TK-dependent drugs. Also, antiviral assays in HeLa TK-deficient cells showed a lack of KAY-
2-41 and KAH-39-149 activities against herpes simplex virus 1 (HSV-1) and HSV-2 TK-deficient mutants. Furthermore, enzy-
matic TK assays showed the ability of HSV-1 TK, VZV TK, and cellular TK1 and TK2 to recognize and phosphorylate KAY-2-41
and KAH-39-149. These results demonstrate that the compounds depend on both viral and host TKs to exert antiviral activity.
Additionally, the antiviral efficacy of KAH-39-149 proved to be superior to that of KAY-2-41 in a mouse model of gammaherpes-
virus infection, highlighting the potential of this class of antiviral agents for further development as selective therapeutics
against Epstein-Barr virus.
Among the diseases associated with Epstein-Barr virus (EBV),one of the more serious complications in transplant patients
is posttransplant lymphoproliferative disorder (PTLD) (1). The
current treatment modalities for PTLD and other EBV-associated
malignancies include conventional cancer therapies, such as che-
motherapy, but also involve anti-CD20 monoclonal antibody
(rituximab) therapy and adoptive transfer of EBV-specific cyto-
toxic T lymphocytes (2). The administration of antiviral agents,
mainly acyclovir (ACV) and ganciclovir (GCV), alone or in com-
bination with these conventional cancer therapies has been used
for prophylaxis (as they can reduce the risk of developing this
disease) and treatment for PTLD (1, 3–6). Nevertheless, antiviral
treatment has been shown to bemoderately effective against EBV-
associated infections in the lytic phase (7). Novel targeted thera-
pies for EBV-related lymphomas are emerging and they are fo-
cused on (i) the activation of lytic viral genes to render the tumor
cells susceptible to antiviral therapies, (ii) the inhibition of down-
stream cell cycle or antiapoptotic pathways that may be activated
by latent EBV proteins, and (iii) the development of an EBV vac-
cine (8).
Mechanism-based inhibitors are currently not available for
EBV (a gammaherpesvirus), in comparison with current antiviral
options (i.e., inhibitors of viral DNA replication) for alpha- and
betaherpesviruses. ACV is highly effective for the treatment of
herpes simplex virus (HSV) infections, but selective pressure of
the drug increases the frequency of ACV resistance, particularly in
immunocompromised patients (9). In immunocompetent indi-
viduals with mucocutaneous disease, long-term therapy with
ACV has not been associated with the development of drug-resis-
tant HSV, but the high ACV resistance rates in patients with re-
current herpetic keratitis raise serious concerns (9–14).Other cur-
rently approved drugs (i.e., foscarnet and cidofovir) are active
against most (cidofovir), but not all (foscarnet), ACV-resistant
mutants, yet they have major limitations in terms of toxicity and
pharmacokinetic liability (14). As a consequence, the emergence
of drug-resistant HSV strains stresses the need for novel antiviral
drugs.
Thionucleosides, such as 4=-thiothymidine, were previously
explored for their potential in antiviral treatment, although their
antiviral activities were masked by severe cytotoxicity (15, 16).
Among the several derivatives of 4=-thiothymidine that were sub-
sequently developed (15–19), 5-iodo-4=-thio-2=-deoxyuridine
(4=-thioIDU) exhibited good activity against many of the herpes-
viruses (18). The mechanism of action of 4=-thioIDU was shown
to be similar to that described for IDU in that it is preferentially
phosphorylated by the thymidine kinase (TK) of vaccinia virus
and HSV, and the triphosphate metabolite is a substrate of the
DNApolymerases in both viruses (18, 20). Another 4=-thiothymi-
dine analog is 1=-methyl-substituted 4=-thiothymidine or KAY-2-
41, which was proven to be a strong inhibitor of orthopoxviruses
(21) but also exerted activity against HSV-1 in vitro (17). The
4=-azido analog of 4=-thiothymidine, designatedKAH-39-149, ex-
hibited promising antiviral activity against human immunodefi-
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ciency virus, but its activity against herpesviruses was not evalu-
ated (22).
In this study, we determined the sensitivities of alpha-, beta-,
and gammaherpesviruses to KAY-2-41 and KAH-39-149. Other
gammaherpesviruses, including the murine gammaherpesvirus
68 (MHV-68), herpesvirus saimiri (HVS), and rhesus rhadinovi-
rus (RRV), were also included in these studies as surrogate viruses
for EBV and Kaposi’s sarcoma-associated herpesvirus (KSHV).
With the aim of better understanding themodes of action of these
two novel antivirals, drug-resistant viruses were selected in vitro,
and enzymatic TK assays were performed. KAY-2-41 and KAH-
39-149 treatment of mice infected with MHV-68 enabled us to
assess their inhibitory effects in vivo.
MATERIALS AND METHODS
Cells and viruses.Murine fibroblasts (NIH 3T3 cells; ATCC CRL-1685),
owl monkey kidney cells (OMK) (ATCC CRL-1556), primary rhesus
monkey fibroblasts (RF) (kindly provided by ScottWong, OregonHealth
and Science University, Beaverton, OR, USA), human embryonic lung
(HEL) fibroblasts (ATCC CCL-137), BCBL-1 (NIH AIDS Research &
Reference Reagent Program), and P3HR-1 cells (ATCC HTB-62) were
grown as previously described (23). HeLa TK cells (thymidine kinase-
deficient human epithelial cell lines derived from a cervical carcinoma)
were kindly provided by Y. C. Cheng, Yale University School ofMedicine,
NewHaven, CT,USA, and grown inDulbecco’smodified Eagle’smedium
(DMEM) (Invitrogen, Merelbeke, Belgium) containing 10% heat-inacti-
vated fetal calf serum (FCS), 2 mM L-glutamine, 0.1 mM nonessential
amino acids, 1 mM sodium pyruvate, and 10 mM HEPES. MHV-68
(clone G2.4; kindly provided by A. A. Nash, Edinburgh, United King-
dom), HVS (strain C-488; ATCC VR-1414), and RRV (strain 17577;
kindly provided by Scott Wong) were replicated in NIH 3T3, OMK, and
RF cells, respectively. The following viruses were replicated in HEL cells:
HSV-1 (KOS strain, ATCC VR-1493), HSV-2 (G strain, ATCC VR-734),
varicella-zoster virus (VZV) strain Oka (ATCCVR-795), and two human
cytomegalovirus (HCMV) strains, AD-169 andDavis (ATCCVR-538 and
ATCC VR-807, respectively).
Viruses bearing mutations in the viral TK and that were previously
selected in our laboratory were also used for antiviral testing: HSV-1 TK-
deficient (TK) KOS strain bearing aG insertion at nucleotides 430 to 436
(24), VZV TK strain 07-1, the MHV-68 TK T364P mutant (G2.4 clone)
(23), and the HVS TK R45stop mutant (C488 strain) (23).
Compounds.KAY-2-41 and KAH-39-149 were synthesized and char-
acterized at Showa University, Tokyo, Japan. Their chemical structures
are shown in Fig. 1. The sources of the compounds used in the antiviral
assays were as follows: HDVD (1-[(2S,4S-2-(hydroxymethyl)-1,3-dioxo-
lan-4-yl]5-vinylpyrimidine-2,4(1H,3H)-dione), synthesized at the Uni-
versity of Georgia College of Pharmacy, Athens, GA, USA; ACV (9-(2-
hydroxyethoxymethyl)guanine), GlaxoSmithKline, Stevenage, United
Kingdom; brivudin (BVDU) [(E)-5-(2-bromovinyl)-1--D-2=-deoxyri-
bofuranos-1-yl-uracil], Searle, United Kingdom; GCV [9-(1,3-dihy-
droxy-2-propoxymethyl)guanine], Roche, Basel, Switzerland; and PFA
(foscarnet, phosphonoformate sodium salt), Sigma Chemicals, St. Louis,
MO; HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine],
and adefovir (PMEA) (9-[2-(phosphonylmethoxyethyl)adenine]), Gilead
Sciences, Foster City, CA; and HPMP-5-azaC (1-(S)-[3-hydroxy-2-(phos-
phonomethoxy)propyl]-5-azacytosine), HPMPA ((S)-9-[3-hydroxy-2-
(phosphonomethoxy)propyl]adenine), HPMPO-DAPy [(R)-(2,4-diamino-
3-hydroxy-6-[2-(phosphonomethoxy)propoxy])pyrimidine], PMEDAP (9-
[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine), and PMEO-DAPy
(2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine), Marcela
Krecmerova, Institute of Organic Chemistry and Biochemistry, Academy of
Sciences of the Czech Republic, Prague, Czech Republic.
Antiviral assays.The drug susceptibilities of all viruses were evaluated
in their corresponding cell lines, as previously described (23). Briefly, for
HSV-1, HSV-2, HCMV, MHV-68, HVS, and RRV, a viral cytopathic ef-
fect (CPE) reduction assay was used, and plaque reduction assays were
performed for VZV. Drug susceptibility assays on HeLa TK mutants
were performed under similar conditions as those carried out with the
HEL cells. The antiviral assays for KSHV and EBV were performed in
BCBL-1 and P3HR-1 cell cultures, respectively, induced to the viral lytic
cycle by adding 20 ng/ml 12-O-tetradecanoylphorbol 13-acetate (TPA)
(Sigma-Aldrich, Bornem, Belgium) to the growing cells. After 5 days,
intracellular DNA was quantified by real-time quantitative PCR (qPCR),
targeting ORF73 of KSHV and BNRF1 of EBV (25). The 50% effective
concentrations (EC50s) were further calculated.
Cytotoxicity assays.The cytostatic effect of the drugswas based on the
inhibition of cell growth (HEL, NIH 3T3, OMK, and RF cells), as previ-
ously described (23). Briefly, HEL cells were seeded at a density of 5103
cells/well into 96-wellmicrotiter plates. NIH3T3,OMK, andRF cells were
seeded at a density of 3  103 cells/well, and uninduced BCBL-1 and
P3HR-1 cells were seeded at densities of 3  105 cells/ml and 1  106
cells/ml, respectively. After 24 h of cell growth, medium containing dif-
ferent concentrations of the test compounds was added. After 3 days of
incubation at 37°C, the cell counts were determined using aCoulter coun-
ter (Analis, Namur, Belgium). The 50% cytostatic concentration (CC50) is
the concentration of the compound required to reduce cell growth by 50%
relative to the number of cells in the untreated controls. Alternatively,
cytotoxicity was expressed as the minimum cytotoxic concentration
(MCC), which is the compound concentration that causes a microscopi-
cally detectable alteration in cell morphology.
Thymidine kinase assay. The assay was performed as previously de-
scribed (23), and the inhibitory activities of KAY-2-41 and KAH-39-149
were determined against [methyl-3H]thymidine (dThd) phosphorylation
by purified cellular TK-1 and TK-2, HSV-1 TK, and VZV TK. Briefly, the
enzymes were incubated at 37°C for 30 min in the presence of different
concentrations of the test compounds in a 50-l reaction mixture con-
taining 50 mMTris-HCl (pH 8.0), 2.5 mMMgCl2, 10 mM dithiothreitol,
0.5mM3-[(3-cholamidopropyl)dimethylammonio]-1-propane-sulfonic
acid, 3mg/ml bovine serum albumin, 2.5mMATP, 1M[methyl-3H]de-
oxythymidine ([methyl-3H]dThd), and enzyme. Forty-five-microliter ali-
quots of the reaction mixtures were spotted on Whatman DE-81 filter
paper disks. The filters were washed three times for 5 min in 1 mM am-
monium formate, once for 1 min in water, and once for 5 min in ethanol.
The radioactivity was determined by scintillation counting.
To determine the monophosphorylation of KAY-2-41, KAH-39-149,
and BVDU by HSV-1 TK, VZV TK, TK1, and TK2, 500 M of the test
compounds was added in the mixture as described above but without
[methyl-3H]dThd. After 0, 30, and 120min of incubation at 37°C, 50l of
phosphate-buffered saline (PBS) and 67% cold methanol were added the
mixture. After centrifugation, the supernatant was injected into the high-
pressure liquid chromatography (HPLC) system (strong-anion exchange
[SAX] column). The relative peak areas of the drugs and theirmonophos-
phate forms were used to determine the enzymatic activities of the TKs.
Selection and characterizationof drug-resistant viruses.Drug-resis-
tant HSV-1, HSV-2, HVS, and MHV-68 isolates were obtained by serial
passages (between 4 and 15 passages) in their respective cell lines in the
presence of increasing concentrations of KAY-2-41 or KAH-39-149
FIG 1 Chemical structures of 4=-thiothymidine, KAY-2-41, and KAH-
39-149.
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(starting at a concentration equivalent to their EC50). After confirming the
resistant phenotype of the parent stock, viruses were plaque purified by
limiting dilution. These clones were used for sequencing of the viral TK
and DNA polymerase genes, as well as the protein kinase genes of
MHV-68 and HVS. Phenotyping of the different viral clones was assessed
by the corresponding antiviral assays.
Animal studies.All animal workwas approved by theKatholiekeUni-
versiteit Leuven Ethics Committee for Animal Care and Use (permit
P097-2010). Intranasal infection of 4-week-old BALB/c mice was per-
formed with MHV-68 (104 PFU/animal) under anesthesia using
ketamine-xylazine in saline. KAY-2-41 and KAH-39-149, diluted in PBS,
were administered intraperitoneally at a dose of 50 mg/kg of body weight
once per day for 5 consecutive days, starting the day of infection. At days
6 and 12 postinfection (p.i.), each mouse was euthanized with a lethal
injection of pentobarbital. The lungs, mediastinal lymph nodes (MLNs),
and spleen were stored at20°C in PBS for DNA extraction, at80°C in
RNAlater (Ambion) for RNA extraction, and then were fixed in 10%
buffered formalin. The fixed tissueswere embedded in paraffin, and 5-m
sections were stained with hematoxylin and eosin stain for histopatholog-
ical examination. Quantification of viral DNA load and relative open
reading frame 73 (ORF73) (latent) and glycoprotein B (gB) (lytic) gene
expression in the tissues was performed as previously described (23).
RESULTS
Antiherpetic activity. The inhibitory effects of KAY-2-41 and
KAH-39-149 against a broad variety of herpesviruses are ex-
pressed as the 50% effective concentration (EC50), and the results
are shown in Table 1. Among the gammaherpesviruses, EBVDNA
synthesis was strongly inhibited by KAY-2-41 (EC50, 0.7M) and
KAH-39-149 (EC50, 0.3 M), whereas none of the compounds
were active against KSHV (EC50,130 M). MHV-68 was more
sensitive to the inhibitory effects of KAH-39-149 than of KAY-
2-41 (EC50s, 0.2Mversus 13M, respectively). In contrast, HVS
and RRV replication were weakly or not inhibited by KAY-2-41
and KAH-39-149.
Both compounds showed antiviral activities against HSV-1
and HSV-2 in the micromolar range (EC50s, 1.4 M to 3.3 M),
but KAH-39-149 was about 2-fold-more potent than KAY-2-41.
The inhibitory effect of KAY-2-41 was weak against the VZV Oka
strain (EC50, 37M), whereas KAH-39-149 proved to be approx-
imately 100-fold-more potent (EC50, 0.4 M). No antiviral activ-
ity was found against the two HCMV strains evaluated. The activ-
ity of the parent compound, 4=-thiothymidine, was previously
reported, and the molecule was found to be active against HSV-1
(EC50, 0.01 M), HSV-2 (EC50, 0.04 M), VZV (EC50, 0.09 M),
and HCMV (EC50, 1 M), and it showed severe inhibition of
fibroblast proliferation (CC50, 0.8 M) (26).
The cytostatic activities of KAY-2-41 andKAH-39-149 onHEL
cells, measured as CC50 values, were 12 M and 10 M, respec-
tively, but both compounds were less cytostatic on P3HR-1 cells
(CC50s, 157 M and 109 M, respectively) and BCBL-1 cells
(CC50s, 75 M and 25 M, respectively) (Table 2). Also, these
drugs did not alter HEL cell morphology at the highest concentra-
tion tested (MCC, 100 M). Thus, the selectivity indices (SIs)
TABLE 1 Antiviral activities of KAY-2-41 and KAH-39-149 against wild-type and mutant herpesviruses
Virus or TK mutant
EC50 (M) (fold resistance) for
a:
KAY-2-41 KAH-39-149 ACV GCV BVDU
Viruses (strains)
HSV-1 (KOS) 3.3 2.1 1.4 1.4 0.1 0.06 0.04 0.01 0.08 0.03
HSV-2 (G) 3.3 1.2 1.5 1.3 0.3 0.1 0.06 0.03 30
VZV (Oka) 37 14 0.4 0.02 5.0 1.2 NDb 0.01 0.02
HCMV (AD-169) 20 4 ND 3.0 1.0 ND
HCMV (Davis) 20 20 ND 5.6 2.3 ND
EBV (P3HR-1) 0.7 0.9 0.3 0.07 3.8 0.9 4.3 3.6 6.9 5.1
KSHV (BCBL-1) 130 200 137 44 6.3 2.4 0.09 0.09
MHV-68 (G2.4) 13 6 0.2 0.05 6.2 1.3 10 5.5 0.1 0.06
HVS (C488) 27 14 42 8 116 49 121 47 6.0 5.4
RRV (VR-1414) 24 5 50 200 32 5 0.4 0.03
TK mutants
HSV-1 TK 26 4.7 (8) 16 3.5 (11) 45 1.5 (450) 47 0 (1,175) 188 40 (2,350)
VZV TK(07/1) 45 (1) 1.4 0.1 (4) 74 21 (15) ND 150 (15,000)
MHV-68 TK T364P 55 11 (4) 1.9 0.4 (10) 6.2 1.8 (1) 10 3 (1) 19 21 (190)
HVS TK R45stop 200 (8) 200 (5) 209 156 (1) 141 25 (1) 468 192 (1,170)
a Data are the mean values of at least three independent experiments standard deviations (SD). EC50, 50% effective concentration, the drug concentration required to reduce
virus plaque formation, CPE, or viral DNA copies by 50%.
b ND, not determined.
TABLE 2 Cytostatic concentrations and selectivity indices of KAY-2-41
and KAH-39-149a
Virus (strain) Cell type
KAY-2-41 KAH-39-149
CC50
b SIc CC50 SI
HSV-1 (KOS) HEL 12 8 4 10 4.5 7
HSV-2 (G) HEL 12 8 4 10 4.5 7
VZV (Oka) HEL 12 8 1 10 4.5 25
HCMV (AD-169) HEL 12 8 1 10 4.5 3
HCMV (Davis) HEL 12 8 1 10 4.5 1
EBV P3HR-1 157 57 224 109 83 363
KSHV BCBL-1 75 19 1 25 7 1
MHV-68 (G2.4) NIH 3T3 3.2 1.0 1 3.4 2.3 15
HVS (C488) OMK 79 48 3 50 1
RRV (VR-1414) RF 112 5 28 1
a The values shown are the averages of three independent experiments SD.
b CC50, 50% cytostatic concentration, the drug concentration required to reduce cell
growth by 50% relative to the number of cells in the untreated controls.
c SI, selectivity index (ratio of CC50 to EC50).
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(calculated by CC50/EC50) of KAH-39-149 against human herpes-
viruses in decreasing order were as follows: 363 for EBV, 25 for
VZV, and 7 for HSV-1 and HSV-2. KAY-2-41 was highly selective
against EBV (SI, 224), whereas only low SIs were found toward
HSV-1 and HSV-2 (SI, 3), and the compound was not selective
against VZV (SI,1). Both KAY-2-41 and KAH-39-149 showed a
cytostatic effect on growing NIH 3T3 cells, with CC50 values of 3
M, but these effects were less pronounced on OMK or RF cells
(CC50,28 M). For both compounds, the MCC values were 50
M and100 M on NIH 3T3 and OMK cells, respectively.
Since the viral TK was reported to be involved in the activation
of various thionucleosides (18), we evaluated the inhibitory effects
of KAY-2-41 and KAH-39-149 against TK mutants of HSV-1,
VZV,MHV-68, andHVS (Table 1). A 4-fold to8-fold reduction
in the sensitivity to KAY-2-41 was observed for theHSV-1,MHV-
68, and HVS TKmutants, while a decrease in the antiviral activity
of KAH-39-149 (up to 11 times) was shown against HSV-1, VZV,
MHV-68, andHVSTKmutants. For the reference antiherpesvirus
TK-dependent drugs (i.e., ACV, GCV, and/or BVDU), the de-
crease in inhibitory activity was much more pronounced than
those for KAY-2-41 and KAH-39-149. These results indicate that
mutations in the herpesvirus TK that give resistance to reference
antiherpesvirus TK-dependent drugs conferred only low levels of
resistance to either KAY-2-41 or KAH-39-149.
Inhibition of TK-catalyzed dThd phosphorylation. Since
herpesvirus TK mutants showed a modest decrease in sensitivity
to KAY-2-41 and KAH-39-149, we further investigated the role of
the viral TK in the mode of action of these nucleoside analogs.
Enzymatic assays with TKs of different origins demonstrated that
KAY-2-41 and KAH-39-149 were able to inhibit the phosphory-
lation of dThd by HSV-1 and VZV TK (Table 3). KAH-39-149
appeared to be a much more potent inhibitor of the viral TK-
catalyzed reaction than KAY-2-41 but exerted less inhibitory ac-
tivity for HSV-1 TK (inhibitory concentration [IC50], 3.0 M)
than its parent compound, 4=-thiothymidine (IC50, 0.09M).The
inhibitory activity of KAH-39-149 was comparable to that of
BVDU, with IC50s of 1.5 M for VZV TK and 2.6 M for HSV-1
TK. Additionally, KAH-39-149 inhibited dThd phosphorylation
catalyzed by cellular TK1 and TK2, with IC50s of 26 M and 6.2
M, respectively, while BVDU inhibited the reaction catalyzed by
TK2 (IC50, 0.4M)but not by TK1 (IC50,500M). dThd phos-
phorylation by cytosolic TK1 was most potently inhibited by 4=-
thiothymidine, with an IC50 of 6.3 M, as previously reported
(26). On the contrary, KAY-2-41was a poor inhibitor of TK1- and
TK2-catalyzed reactions (IC50s, 500 M and 321 M, respec-
tively). These results showed that both thionucleosides are inhib-
itors of viral and cellular TKs and that KAH-39-149 is a better
inhibitor of dThd phosphorylation than is KAY-2-41.
Phosphorylation of KAY-2-41 and KAH-39-149 by viral and
cellular TKs. In order to determine whether viral and cellular TKs
are able to phosphorylate KAY-2-41 and KAH-39-149 to the
monophosphate form, the products generated from the enzy-
matic reaction were resolved by HPLC (Table 3). Although KAY-
2-41, KAH-39-149, and BVDU were phosphorylated by HSV-1
andVZVTK, both enzymes preferentially phosphorylated BVDU,
as approximately 10-fold-higher levels of the monophosphate
form were detected for BVDU compared to those of KAY-2-41
andKAH-39-149. Yet approximately 0.6%of themonophosphate
forms of KAY-2-41 and KAH-39-149 was produced byHSV-1 TK
and VZV TK after 120 min. At this time point, approximately 1%
of the monophosphate forms were produced by cytosolic TK1 for
KAY-2-41 and KAH-39-149. Mitochondrial TK2 did phosphory-
late KAY-2-41 and KAH-39-149, but the highest levels of the
monophosphate formwere observed for BVDU(17%versus 2.3%
for KAY-2-41 and 4.8% for KAH-39-149).
Inhibition of HSV-1 and HSV-2 wild-type and mutant
strains by KAY-2-41 and KAH-39-149 in HeLa TK cells. We
further examined the inhibitory effects of KAY-2-41 and KAH-
39-149 against HSV-1 and HSV-2 wild-type (WT) and TK
strains in HeLa cells deficient in TK1 in order to further assess the
roles of cellular and viral TKs in the mode of action of these thio-
nucleosides. HSV-1 and HSV-2 WT strains were sensitive to the
inhibitory effects of KAY-2-41 and KAH-39-149 in HeLa TK
cells, with EC50s in the range of 13 M and 3 M, respectively
(Table 4). In contrast, these compounds lost their antiviral activ-
ities against HSV-1 andHSV-2 TK strains (EC50s,147Mand
40M, respectively). As a control, we observed amarked reduc-
TABLE 3 Inhibitory activities of KAY-2-41, KAH-39-149, and BVDU on dThd phosphorylation and phosphorylation of these drugs by
2=-deoxynucleoside kinases from different origins
Compound
IC50 (M) for
a: % of nucleoside monophosphate formb
HSV-1 TK VZV TK TK1 TK2 HSV-1 TK VZV TK TK1 TK2
KAY-2-41 49 1 272 21 500 321 16 0.6 0.07 0.5 0.2 0.9 0.2 2.3 0.4
KAH-39-149 3.0 0 1.4 0.7 26 11 6.2 2.3 0.5 0.04 0.7 0.1 0.9 0.3 4.8 0.01
BVDU 2.6 1.5 1.5 0.4 500 0.4 0.05 7.0 0.04 5.8 0.3 0 17 1.3
4=-Thiothymidine 0.09c 6.3c
a The IC50 is the 50% inhibitory concentration of the test compounds, which was calculated as the compound concentration required to inhibit TK-catalyzed [methyl-
3H]dThd
(1M) phosphorylation by 50%. The data are mean values from two independent experiments SD.
b Values represent the percentage of the respective drug monophosphate form present in the reaction mixture after 120 min of incubation of the nucleoside with viral or cellular
TK. The data are the mean values of two independent experiments SD.
c Mean values of two experiments. The SD was never20% of each reported value (data from reference 26).
TABLE 4 Antiviral activities of KAY-2-41 and KAH-39-149 against
wild-type and mutant HSV-1 and HSV-2 in HeLa TK cells
Virus
EC50 (M) for
a:
KAY-2-41 KAH-39-149 ACV GCV PFA
HSV-1 WT 13 0.8 3.6 0.4 0.3 0.1 0.6 0.05 286 0
HSV-1 TK 147 40 14 15 13 9 163 95
HSV-2 WT 13 1.1 2.7 0.6 0.5 0.2 0.1 0.04 179 38
HSV-2 TK 147 40 28 9 7.8 2.8 252 50
a EC50 (50% effective concentration) is the drug concentration required to reduce
virus-induced CPE by 50%. The data are the mean values of three independent
experiments SD.
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tion in the activities of ACV and GCV against TK HSV-1 and
HSV-2, while the antiviral effect of the TK-independent viral
DNA polymerase inhibitor foscarnet (PFA) remained unaffected.
These results demonstrated that KAY-2-41 and KAH-39-149 lost
their activities when both HSV TK and cellular TK1 were absent,
suggesting that both of these TKs are able to activate the com-
pounds.
Genotypic analysis of in vitro-selected drug-resistant her-
pesvirus strains. To further understand the mode of action of
KAY-2-41 and KAH-39-149, drug-resistant viruses were selected
under pressure of each thiothymidine derivative (Table 5).
HSV-1, HSV-2, HVS, and MHV-68 were serially passaged in in-
creasing concentrations of each compound. Different indepen-
dent selection procedures were performedwith theHSV-1 strains,
indicated as KOS/A, KOS/B, KOS/C, and KOS/D, and HSV-2
strains, indicated as G/A, G/B, and G/C (Table 5). The different
viral stocks were then tested for their drug susceptibility pheno-
types in CPE reduction assays, and when a drug-resistant profile
was observed, the clones of each drug-resistant virus were further
isolated. These clones were then used for genotyping. Based on the
proposed mode of action of the thionucleosides (18), the viral TK
andDNA polymerase genes were sequenced, as well as the protein
kinase genes from the HVS andMHV-68 clones. As shown in Fig.
2, several mutations were identified in the viral TK and they con-
sisted of single nucleotide substitutions, insertions, or deletions.
None of the clones carriedmutations in the viral DNApolymerase
or in the protein kinase genes of MHV-68 and HVS.
Under selective pressure of KAY-2-41, an insertion of a single
guanosine (G) was identified between nucleotides 430 and 436 in
a stretch of a homopolymer of seven Gs, resulting in a frameshift
mutation in theHSV-1 TK. Thismutationwas observed inHSV-1
clones isolated from two independent selection procedures
(KOS/A and KOS/D). KAY-2-41-resistant (KAY-2-41r) HSV-1
clones isolated from the two other selection procedures (KOS/B
and KOS/C) showed single nucleotide substitutions leading to the
following amino acid substitutions: R51W, I235F, and R222C.
HSV-2 clones selected under pressure of KAY-2-41 carried a
frameshift mutation resulting from an insertion of one G between
nucleotides 433 and 439. Other HSV-2 mutants harbored single
amino acid substitutions, including Y88C, M129T, S182N, and
T288M.
All KAY-2-41r MHV-68 clones showed the C372W substitu-
tion in the viral TK. Among the HVS clones isolated under pres-
sure of KAY-2-41, different amino acid substitutions and frame-
shift mutations were identified and consisted of E54stop, P326T,
the deletion of one adenine (A) between nucleotides 440 and 445,
and the insertion of one A between nucleotides 1094 and 1095.
Under KAH-39-149 pressure, all HSV-1 clones carried the
V187M amino acid substitution, and HSV-2 clones showed the
Y173C substitution. An insertion of A between nucleotides 1094
and 1095 was found in all KAH-39-149r HVS clones and, in two
MHV-68 clones, an insertion of C occurred in a string of five Cs at
nucleotide positions 661 to 665 in the viral TK.
Phenotypic analysis of the different mutants. To assess the
levels of drug resistance of the viral TKmutants isolated following
KAY-2-41 and KAH-39-149 pressure, drug susceptibility profiles
TABLE 5 Genotypic characterization of drug-resistant herpesvirus TK mutants obtained in vitro under selective pressure of KAY-2-41 and KAH-39-
149a
Viruses by compound Strain selection
No. of
clones/no. total
Nucleotide change in
viral TKb
Amino acid substitution or
frameshift in viral TKb
KAY-2-41
HSV-1 KOS/A 1/6 nt 430–436, G insertion Frameshift
5/6 C151T R51W
KOS/B 6/6 C664T R222C
KOS/C 2/6 C664T R222C
4/6 A703T I235F
KOS/D 4/4 nt 430–436, G insertion Frameshift
HSV-2 G/A 2/2 nt 433–439, G insertion Frameshift
G/B 4/5 nt 433–439, G insertion Frameshift
1/5 C863T T288M
G/C 1/4 A263G Y88C
1/4 T385C M129T
1/4 G545A S182N
1/4 nt 433–439, G insertion Frameshift
MHV-68 G2.4/A 3/3 T1116G C372W
HVS C488/A 1/6 G160T E54stop
1/6 C976A P326T
2/6 nt 440–445, A deletion Frameshift
2/6 nt 1094–1095, A insertion Frameshift
KAH-39-149
HSV-1 KOS/A 5/5 G159A V187M
KOS/C 4/4 G159A V187M
HSV-2 G/B 5/5 A518G Y173C
MHV-68 G2.4/A 2/2 nt 661–665, C insertion Frameshift
HVS C488/A 3/3 nt 1094–1095, A insertion Frameshift
a TK, thymidine kinase.
b No mutations were found in the viral DNA polymerase or in the gammaherpesvirus protein kinase. nt, nucleotides.
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were determined (Fig. 3 and 4). We also calculated the ratio of
EC50mutant to EC50WT, representing the fold resistance.
For HSV-1, mutants with a frameshift (G-string insertion) or
an amino acid substitution in the ATP-binding site (R51W) had
the highest levels of resistance to KAY-2-41 and KAH-39-149
(ranging from13- to 20-fold), aswell as toACV,GCV, andBVDU,
compared to that of WT virus (Fig. 3A). In general, the I235F,
R222C, and particularly V187M HSV-1 mutants showed lower
levels of resistance against KAY-2-41 and KAH-39-149 (ranging
from2- to 7-fold) and also lower levels of resistance toACV,GCV,
and BVDU than the R51W and frameshift TK mutants.
The HSV-2 mutant viruses (G insertion, Y88C, M129T,
S182N, and T288M) isolated under pressure of KAY-2-41 showed
2- to 5-fold resistance against KAY-2-41 and KAH-39-149, except
for the S182Nmutant, which remained sensitive to KAH-39-149.
In contrast, the Y137C amino acid change conferred 2-fold resis-
tance to KAH-39-149 but no resistance to KAY-2-41. Notably, the
sensitivities of the HSV-2 mutants to ACV and GCV were mark-
edly reduced, ranging from 10- to 600-fold compared to that of
the WT virus (Fig. 3B). The HSV-2 TK mutant with a frameshift
(G-string insertion) mutation showed markedly lower levels of
resistance for the thiothymidine analogs than did the HSV-1 TK
mutants with the same type of mutation (2- to 4-fold for HSV-2
versus 13- to 20-fold for HSV-1).
HVS clones bearing an insertion or a deletion of a single nu-
cleotide in the viral TK gene, as well as the E54stop and P326T
amino acid substitutions, conferred noticeable levels of resistance
to KAY-2-41 and KAH-39-149 (Fig. 4A). Yet a much higher de-
gree of resistance was foundwith other TK-dependent drugs, such
as the pyrimidine derivatives BVDU and HDVD (23). However,
for these compounds, the EC50s calculated for the HVS TK mu-
tants were higher than the highest concentrations used in the phe-
notypic assays, which were 200 M for KAY-2-41 and KAH-39-
149, 600 M for BVDU, and 700 M for HDVD. The HVS TK
mutants showed no altered sensitivities to ACV and GCV, which
are known to be dependent on the virus protein kinase (ORF36)
for their activation.
MHV-68 clones bearing the C372W TK amino acid substitu-
tion showed higher EC50s for KAY-2-41, KAH-39-149, BVDU,
andHDVD than did theWT, and 4- and 5-fold levels of resistance
were observed against KAY-2-41 and KAH-39-149, respectively
(Fig. 4B). TheMHV-68 TKmutant with a frameshift (C insertion,
nucleotides [nt] 661 to 665) showed higher levels of resistance to
KAY-2-41 and KAH-39-149 (3- and 15-fold, respectively), as well
as BVDUandHDVD (26- and 115-fold), compared to theC372W
TK mutant.
No changes in the sensitivity of HPMPC were observed between
the WT virus and the various TK mutants. Other acyclic nucleoside
phosphonates, i.e., HPMPA, HPMP-5-azaC, HPMPO-DAPy,
PMEO-DAPy, and the pyrophosphate analog PFA, were also in-
cluded in the phenotypic assays, showing no variations in the
EC50s between the WT and the different TK mutant viruses (data
not shown).
In vivo activity. The in vitro antiviral activities and selectivities
of KAY-2-41 and KAH-39-149 were the most promising against
EBV replication, and therefore we aimed to assess their in vivo
activities in amousemodel of gammaherpesvirus infection. Intra-
nasal infection of BALB/c mice with MHV-68 results in an acute
productive infection of alveolar lung epithelial cells (23, 27). Next,
the virus enters the mediastinal lymph nodes (MLNs) and estab-
lishes a latent infection in the spleen (28). Previously, we deter-
mined the kinetics of gene expression of two genes, the glycopro-
tein B (gB) gene,mainly expressed during lytic replication, and the
ORF73 gene, mainly expressed during latency, in this mouse
model (23). We showed that following a rapid onset, both gB and
ORF73 expression peaked in the lungs after 4 and 6 days postin-
FIG 2 Mapping of amino acid changes and frameshift mutations in the herpesvirus TK selected under pressure of KAY-2-41 and KAH-39-149. Shown is a
schematic representation of the TK of HSV-1, MHV-68, and HVS. The ATP-binding site, the nucleoside-binding site, and the regions conserved among
herpesvirus TKs are indicated by black boxes. Amino acid changes and frameshiftmutations in the herpesvirus TK that have not previously been reported in vitro
or in patients are underlined. nts, nucleotides.
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fection (p.i.), whereas gene expression peaked at approximately 12
to 14 days p.i. in the spleen. BALB/c mice were infected intrana-
sally and treated intraperitoneally with 50 mg/kg of KAY-2-41 or
KAH-39-149 once a day for 5 days, starting 2 h after infection. To
evaluate drug efficacy, we examined (i) the inhibition of acute
MHV-68 replication in the lungs after 6 days p.i. and (ii) the effect
of antiviral treatment on the establishment of viral latency in
MLNs and the spleen after 12 days p.i. To this end, viral DNA
copies, as well as the expression of lytic gB and the latent ORF73
gene, were determined (Fig. 5).
At day 6 p.i., the viral DNA load in the lung tissue of the un-
treated infected control was as high as 106 copies/mg (Fig. 5A). In
the drug-treated mice, viral DNA copies were significantly re-
duced by 1.5 log for KAY-2-41 and by 3 log for KAH-39-149.
KAY-2-41 treatment also decreased the relative expression levels
of a lytic gene (gB) and a latent gene (ORF73) by approximately
one log compared to the infected control, whereas KAH-39-149
was more potent in reducing gB and ORF73 expression levels in
the lungs of infected mice (by approximately 2 log) (Fig. 5B). In
the MLNs, but particularly in the spleen, KAY-2-41-treated ani-
FIG 3 Phenotyping of drug-resistant HSV isolates bearing mutations in the viral TK. The data are presented as a dot plot of the EC50s of drug-resistant HSV-1
(A) and HSV-2 (B) versus the EC50 for wild-type (WT) virus. The horizontal bars indicate the mean values of three independent experiments.
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mals harbored reduced MHV-68 DNA copies compared with the
control group. In contrast, viral DNA copies were not detected in
these tissues after KAH-39-149 treatment (Fig. 5A).
At day 12 p.i., the untreated infected mice showed low num-
bers of viral DNA copies in the lungs (103 copies/mg). At this time
point, viral DNA copies were still significantly reduced in the
lungs of the KAY-2-41-treated mice (P 	 0.004) but not of the
KAH-39-149-treated mice (Fig. 5A). Yet gB and ORF73 expres-
sion was not significantly lower in the lungs of KAY-2-41-treated
animals than that in those of the control group (Fig. 5B). In the
MLNs, similar levels of viral DNA loads were observed between
the control and KAY-2-41-treated groups, while three out of five
KAH-39-149-treated mice showed the presence of MHV-68
DNA. Nevertheless, the five mice of the KAH-39-149-treated
group did not harborMHV-68DNA copies in the spleen at day 12
p.i. (P 	 0.0008) (Fig. 5A). In line with this, the KAH-39-149-
treated animals did not show gB or ORF73 expression in this tis-
sue. Thus, until 12 days p.i., KAH-39-149 treatment was able to
FIG 4 Phenotyping of drug-resistant gammaherpesvirus isolates bearing mutations in the viral TK. The data are presented as a dot plot of the EC50s of
drug-resistant HVS (A) and MHV-68 (B) versus the EC50 for wild-type (WT) virus. The horizontal bars indicate the mean values of three independent
experiments.
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FIG 5 Analysis ofMHV-68 infection in different organs of untreated and treatedmice at the acute and latent stages. (A) Viral DNA copies were quantified in the
lungs, mediastinal lymph nodes (MLNs), and spleens of intranasally infected mice (104 PFU of MHV-68) and treated intraperitoneally with KAY-2-41 and
KAH-39-149 for five consecutive days. Each group contained five mice. The values are given as the mean log viral copy number per mg of tissue  standard
deviation (SD). The dashed line represents the limit of detection set on 10 copies of viral DNA. (B) The upper panels represent the level of gB (white bars) and
ORF73 (black bars) expression relative to those of the untreated control and normalized to the endogenous control glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). The error bars display the calculated maximum (RQMax) and minimum (RQMin) expression levels that are equivalent to the standard error of the
mean expression level (RQ value). The RQMax is represented as 

CT s and the RQMin as 

CT s, where s is the SD of the 

CT value. The lower panels
represent the 1/delta CT values obtained from each mouse in the untreated and treated groups, and on which the Mann-Whitney U tests were done to compare
the untreated and treated groups: *, P 0.05; **, P 0.01; ***, P 0.001. The dashed line represents the limit of detection.
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inhibit the spread of MHV-68 to the spleen; while less active,
KAY-2-41 still significantly diminished MHV-68 loads in this
tissue.
At day 6 p.i., a histological examination of lung tissue inMHV-
68-infected mice showed a diffusely increased interstitial cellular-
ity, particularly at the perivascular and peribronchial sites, com-
pared to that in the uninfected control mice. At day 12 p.i., this
inflammatory reaction was dominated by mononuclear cells (Fig.
6). After treatment with KAY-2-41 and KAH-39-149, a similar
inflammatory reaction was present in the lungs of the virus-in-
fected treatedmice. The white pulp of the spleens of theMHV-68-
infected untreated and KAY-2-41-treated mice was composed of
large poorly delineated lymphoid follicles and an unremarkable
red pulp. In addition, tingible body macrophages were noted in
the white pulp of the spleens of the untreated and KAY-2-41-
treated infected mice but not in the KAH-39-149-treated mice.
DISCUSSION
In this report, we demonstrate the inhibitory activities of KAY-
2-41 and KAH-39-149 against alpha- and gammaherpesviruses,
which are dependent on phosphorylation by viral and cellular
TKs. The antiviral activity of KAH-39-149 was superior to that of
KAY-2-41 against HSV-1, HSV-2, VZV, EBV, and MHV-68. It
was previously shown that the parent molecule 4=-thiothymidine
was also an inhibitor of herpesvirus replication; however, this
drug demonstrated considerably higher cellular toxicity than
KAY-2-41 and KAH-39-149 (26). Among all herpesvirus evalu-
ated here, both compounds were the most active against EBV,
with 5- to 10-fold higher anti-EBV activity than that against ACV,
GCV, andHPMPC. The guanosine analogs ACV andGCV are the
antiviral drugs commonly administered off-label for the treat-
ment of EBV-associated malignancies, and the acyclic nucleoside
phosphonate HPMPC exhibits selective anti-EBV activity in vitro
(3, 29). KAY-2-41 and KAH-39-149 were poorly active against
KSHV and two genetically related rhadinoviruses, HVS and RRV.
Since our findings showed the involvement of viral TK in the
mode of action of the thionucleosides, future studies aimed at
determining the affinity and phosphorylation capacity of EBV TK
for KAY-2-41 and KAH-39-149 would be helpful for assessing the
eventual contribution of EBV TK to the selective inhibition of
EBV replication by these drugs.
In contrast to the study of Rahim et al. (19), which reported
that thionucleosides may be poor substrates of HSV-2 TK, and
despite the fact that HSV-2 TK does not exhibit thymidylate ki-
nase activity, KAY-2-41 and KAH-39-149 showed pronounced
antiviral activity against this virus. Still, HSV-2 TKmutants with a
frameshift mutation exhibited approximately 5-fold-lower levels
of resistance for KAY-2-41 and KAH-39-149 than the HSV-1 TK
mutantwith a similarmutation, but this was not seen forACVand
GCV. These results might indicate that the activities of the 4=-
thiothymidine derivatives are more dependent on the phosphor-
ylation by cellular kinases in HSV-2-infected cells than in HSV-1-
infected cells. Furthermore, the enzymatic assays demonstrated
that KAH-39-149 had a higher inhibitory effect on the phosphor-
FIG 6 Histopathological analysis of lungs and spleen of uninfected, infected, and treated infected mice. Shown are hematoxylin and eosin staining of the lung
tissues of uninfected mice, MHV-68-infected mice, KAY-2-41-treated mice, and KAH-39-149-treated mice at days 6 and/or 12 p.i. The histopathology of the
spleen at day 12 p.i. is shown in the right panels, and the black arrows indicate the presence of tingible body macrophages in the spleens of the infected mice.
Magnification,20 (inset,100).
Antiherpetic Activity of Thiothymidine Derivatives
August 2014 Volume 58 Number 8 aac.asm.org 4337
 o
n
 Septem
ber 25, 2014 by KU Leuven University Library
http://aac.asm
.org/
D
ow
nloaded from
 
ylation of dThd catalyzed by HSV-1 and VZV TK than did KAY-
2-41. These results are consistent with the higher antiviral activity
of KAH-39-149 against HSV-1 and VZV, notwithstanding that
the viral TK activity was similar for these drugs and that the viral
DNA polymerase likely represents the final target responsible for
virus inhibition.
As mentioned above, our data demonstrate that not only her-
pesvirus TKs but also the cellular TK1 are needed for the full
antiviral effects of KAY-2-41 andKAH-39-149. Evidence support-
ing the involvement of these TKs was obtained by an evaluation of
the sensitivities of TK herpesviruses, e.g., HSV-1, VZV, MHV-
68, and HVS, to KAY-2-41 and KAH-39-149. These mutants
showed modest decreases in sensitivity (4- to 11-fold) to these
drugs, while they were markedly resistant to other TK-dependent
drugs (ACV, GCV, and/or BVDU), with levels of resistance in the
range of 100- to 1,000-fold (Table 1); this might point toward the
ability of cellular kinases to activate the thionucleosides. Similar
observations were made with our KAY-2-41r and KAH-39-149r
herpesvirus mutants, and our data are in agreement with those
reported for another thionucleoside, 4=-thioIDU (18). In addi-
tion, in all the different herpesviruses replicated under pressure of
KAY-2-41 and KAH-39-149, various mutations were identified in
the viral TK and not in the DNA polymerase or protein kinase (of
gammaherpesviruses). In agreement with this, a functional viral
TK was necessary for HSV-1 and HSV-2 to remain sensitive to
each of the thionucleoside derivatives in cells defective in TK1
(HeLa TK cells). Additionally, KAH-39-149, and to a lesser ex-
tent KAY-2-41, inhibitedHSV-1 andVZVTKs, as well as cytosolic
TK1 and mitochondrial TK2 dThd phosphorylation. Finally,
KAY-2-41 and KAH-39-149 were shown to be phosphorylated to
their monophosphate forms by HSV-1 TK, VZV TK, TK1, and
TK2. These results further support that the viral TK and cytosolic
TK1 are the kinases involved in the activation of these 4=-thiothy-
midine derivatives. Although the thionucleoside derivatives were
phosphorylated in vitro byTK2, the role of TK2 in the activation of
the cell compounds appears to be minor, because no activity of
KAY-2-41 or KAH-39-149 against TKHSVmutants was seen in
the HeLa cells that lacked TK1. However, to further work out the
mechanism of action of KAY-2-41 and KAH-39-149, metabolic
studies are required to assess the formation of the active metabo-
lite (triphosphate form) and the incorporation of these com-
pounds into DNA by DNA polymerases.
In line with our findings, Prichard et al. (18) provided further
evidence supporting that besides viral kinases, cellular kinases
may be implicated in the first phosphorylation step of thionucleo-
sides. The anti-HSV-1 activity of 4=-thioIDU was reduced by 10-
fold against anACVr TKmutant, while a100-fold reduction in
the efficacy of ACVwas observed. Also, the compound was incor-
porated into the viral DNA of HCMV-infected cells, yet HCMV
does not encode a TK homolog, and the UL97 (protein kinase)
was not shown to contribute significantly to the phosphorylation
of 4=-thioIDU. The triphosphate form of 4=-IDU was most prob-
ably produced by cellular kinases. Therefore, these data support a
model for the mechanism of action of KAY-2-41 and KAH-39-
149. As the drugs are converted to their monophosphate forms by
the herpesvirus and cellular TKs, we hypothesize that they may
further inhibit DNA synthesis by either incorporation into DNA
or inhibition of the viral DNA polymerase after two subsequent
phosphorylations by cellular nucleoside kinases.
Mitochondrial TK2 has an important role in the maintenance
of deoxynucleoside triphosphate pools in the mitochondria and
has been suggested to contribute to the mitochondrial toxicity of
pyrimidine nucleoside analogues (30). It could be asked whether
the antiviral activities seen against HSV-1, HSV-2, VZV, and
MHV-68might be related in part to cytostatic effects, as KAH-39-
149 was particularly able to inhibit TK2 activity. Yet no inhibitory
activity was observed against HCMV, which was evaluated in the
same cell type as HSV-1, HSV-2, and VZV. In addition, the anti-
viral assays were performed on confluent monolayers, for which
KAY-2-41 and KAH-39-149 had anMCC value of100M, and
not on growing cells, for which low CC50 values were obtained.
Similarly, the anti-EBV and anti-KSHV activities of KAY-2-41
and KAH-39-149 were evaluated in dividing lymphocytes, and
whereas KSHV was not inhibited by these drugs, they were highly
selective against EBV, with minimal cytostatic effects. Therefore,
we assumed that the antiherpesvirus activity is likely related to the
inhibition of viral DNA synthesis rather than to mitochondrial
toxicity, but this should still be evaluated in further studies. Nev-
ertheless, immunofluorescence studies have suggested that 4=-
thioIDUmight be incorporated into the DNA of uninfected cells,
indicating that the triphosphate form was a substrate for the cel-
lular DNA polymerase (18). While this may have accounted for
the inhibition of cell proliferation seen with 4=-thioIDU, one may
speculate that it is a situation comparable to those of KAY-2-41
and KAH-39-149. Yet, no noticeable signs of toxicity (i.e., weight
loss) were seen in mice repetitively treated with each of the drugs
for 5 days, once per day.
Although cellular kinases might be involved in the phosphor-
ylation of these thiothymidine derivatives, drug-resistant HSV-1,
HSV-2, HVS, and MHV-68 clones that were selected under pres-
sure of KAY-2-41 and KAH-39-149 all harbored mutations in the
viral TK, indicating that these antiviral agents interact with the
viral TK. In HSV-1 clinical isolates, the most common TK muta-
tion described to date is a single G insertion in the run of seven
guanosine nucleotides from nucleotide positions 433 to 439,
which appears to be a hot spot for mutations (31). This frameshift
mutation localized closed to the nucleoside-binding site, leading
to the production of a truncated TK polypeptide (32, 33). In this
study, we found this mutation in HSV-1 and HSV-2 clones repli-
cated under pressure of KAY-2-41. Other previously known drug
resistance mutations mapped in the TK of HSV-1 and HSV-2 of
clinical samples have been also identified here, such as the amino
acid substitutions R51W, R222C, V187M, S182N, T288M, and
Y173C (13, 24, 34–41). Three amino acid changes in the HSV TK
were never reported before, i.e., I235F, Y88C, and M129T.
Strikingly, amino acid changes in the TK of HSV-1 (V187M,
R222C, and I235F) that conferred the lowest levels of resistance
against ACV, GCV, and BVDU were also associated with low
levels of resistance to KAY-2-41 and KAH-39-149. Similar ob-
servations were made in HSV-1 clones harboring mutations
that conferred the highest level of resistance against all TK-
dependent drugs.
While drug resistance has not yet been studied in detail for
gammaherpesviruses, we recently isolated a drug-resistant HVS
mutant under pressure of HDVD, a pyrimidine nucleoside that
depends on the viral TK for its activation, and this clone had a
P326T amino acid substitution located in the nucleoside-binding
site of the TK (23). Here, we selected the P326T HVS mutant
under pressure of KAY-2-41, and in line with our previous study,
we observed cross-resistance to other TK-dependent drugs, i.e.,
Coen et al.
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BVDU and HDVD. Besides the P326T amino acid substitution in
HVS, the Y173C amino acid substitution in HSV-2 TK also oc-
curred in the substrate binding site, and more precisely, both
changes are located in a motif of three conserved amino acids,
presented as CYP in HSV-2 TK (positions 172 to 174) and VFP in
HVS (positions 324 to 326). Previously, Munir et al. (42) revealed
that in the nucleoside-binding site encoded by HSV-1, a high de-
gree of flexibility in accommodating different types of amino acid
substitutions existed. However, no replacement of the proline res-
idue was tolerated at position 173 of HSV-1 TK (corresponding to
Pro174 in HSV-2 and Pro326 in HVS), whereas the tyrosine resi-
due at position 172 (HSV-1) could be replaced by the structurally
related phenylalanine only (42). Consistent with this study,Wu et
al. (43) reported that in EBV, the full activity of the TK was re-
tained only when a tyrosine residue replaced the phenylalanine at
this position. Thus, the very limited substitution of proline and
tyrosine/phenylalanine in the conserved site IV (i.e., nucleoside-
binding site) suggests that these residues are essential for main-
taining functional TK activity (42, 43).
Furthermore, the inhibitory effects of KAY-2-41 and KAH-39-
149 were demonstrated in vivo in a mouse model of gammaher-
pesvirus infection, which proved that KAH-39-149 was superior
to KAY-2-41 in inhibitingMHV-68 replication and both lytic and
latent gene expression in the lungs (day 6 p.i.), as well as viral
dissemination to other organs (MLNs and spleen). A similar
course of infection was previously observed after treatment with
HPMPC but not with the pyrimidine analog HDVD (23, 29). In
addition, we evaluated KAY-2-41 and KAH-39-149 in athymic
nude mice infected intracutaneously with HSV-1; however, both
drugs did not show antiviral efficacy in this model (our unpub-
lished data). Indeed, the treatment of HSV-1-infected mice with
KAY-2-41 and KAH-39-149, administered topically at 1% and
0.3% twice daily, did not reduce the development of lesions and
mortality among the infected animals. The failure of drug treat-
ment in HSV-1-infected mice compared to that in MHV-68-in-
fected mice might be related to differences in (i) the route of
infection (intracutaneously versus intranasal) and/or (ii) patho-
genicity, as HSV-1 led to severe disease development and further
death of the infected animals. Additionally, as reported by Prich-
ard et al. (18), the thionucleoside 4-thioIDU was not effective at
reducing the mortality of mice infected with HSV-2 by the intra-
nasal route and treated orally with the drug at a dose of up to 30
mg/kg.
The data presented here prove that KAH-39-149 is an active
and selective inhibitor of EBV replication in cell culture and in a
mouse model of gammaherpesvirus acute infections (44, 45). Al-
though KAY-2-41 showed less efficacy in vivo, our study demon-
strated that 1=-substituted- and 4=-substituted-4=-thiothymidine
derivatives should be considered attractive classes of antiviral
agents. The in vitro results presented here strongly suggest that the
mechanism of action of KAY-2-41 and KAH-39-149 involves
phosphorylation by viral and cellular TKs prior to inhibition of
the viral DNA polymerase. Still, further investigations, such as
metabolic studies andmarker transfer experiments, are needed to
support the proposed mode of action in order to determine the
impact of specific mutations in the herpesvirus TK on the activity
of the thionucleosides. Besides the promising anti-EBV activities
of these drugs, the development of new thionucleoside derivatives,
with a higher affinity for herpesvirus TKs, may offer enhanced
selectivity against HSV-1, HSV-2, and VZV.
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